OncoMatch/Clinical Trials/NCT07724535
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
Is NCT07724535 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies 18F-grazy-02 for cancer.
Treatment: 18F-grazy-02 — This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Melanoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Low WBC (less than 3 x 10^9/L) [excluded]
Severe hepatic or renal dysfunction; Low WBC (less than 3 x 10^9/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07724535 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages